Asset profile
Racotumomab
Monoclonal antibody
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT01240447: The study was randomized and had a supportive-care comparator, but it was unblinded and extremely small, with only 7 participants. Its listed primary outcomes focused mainly on safety and immune laboratory measures rather than a clinical efficacy endpoint, and no primary comparison results are available.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.